Molly Jung1, Bethany Warren1, Morgan Grams1,2, Yuenting D Kwong3, Tariq Shafi1,2, Josef Coresh1, Casey M Rebholz1, Elizabeth Selvin1,2. 1. Department of Epidemiology and the Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins School of Public Health, Baltimore, Maryland, USA. 2. Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland, USA. 3. Division of Nephrology, University of California San Francisco, San Francisco, California, USA.
Abstract
BACKGROUND: In people with chronic kidney disease (CKD), HbA1c may be a problematic measure of glycemic control. Glycated albumin and fructosamine have been proposed as better markers of hyperglycemia in CKD. In the present study we investigated associations of HbA1c, glycated albumin, and fructosamine with fasting glucose by CKD categories. METHODS: A cross-sectional analysis was performed of 1665 Atherosclerosis Risk in Communities Study participants with diagnosed diabetes aged ≥65 years. Spearman's rank correlations (r) were compared and Deming regression was used to obtain root mean square errors (RMSEs) for the associations across CKD categories defined using estimated glomerular filtration rate and urine albumin:creatinine ratio. RESULTS: Correlations of HbA1c, glycated albumin, and fructosamine with fasting glucose were lowest in people with severe CKD (HbA1c r = 0.52, RMSE = 0.91; glycated albumin r = 0.39, RMSE = 1.89; fructosamine r = 0.41, RMSE = 1.87) and very severe CKD (r = 0.48 and RMSE = 1.01 for HbA1c; r = 0.36 and RMSE = 2.14 for glycated albumin; r = 0.36 and RMSE = 2.22 for fructosamine). Associations of glycated albumin and fructosamine with HbA1c were relatively similar across CKD categories. CONCLUSIONS: In older adults with severe or very severe CKD, HbA1c, glycated albumin, and fructosamine were not highly correlated with fasting glucose. The results suggest there may be no particular advantage of glycated albumin or fructosamine over HbA1c for monitoring glycemic control in CKD.
BACKGROUND: In people with chronic kidney disease (CKD), HbA1c may be a problematic measure of glycemic control. Glycated albumin and fructosamine have been proposed as better markers of hyperglycemia in CKD. In the present study we investigated associations of HbA1c, glycated albumin, and fructosamine with fasting glucose by CKD categories. METHODS: A cross-sectional analysis was performed of 1665 Atherosclerosis Risk in Communities Study participants with diagnosed diabetes aged ≥65 years. Spearman's rank correlations (r) were compared and Deming regression was used to obtain root mean square errors (RMSEs) for the associations across CKD categories defined using estimated glomerular filtration rate and urine albumin:creatinine ratio. RESULTS: Correlations of HbA1c, glycated albumin, and fructosamine with fasting glucose were lowest in people with severe CKD (HbA1c r = 0.52, RMSE = 0.91; glycated albumin r = 0.39, RMSE = 1.89; fructosamine r = 0.41, RMSE = 1.87) and very severe CKD (r = 0.48 and RMSE = 1.01 for HbA1c; r = 0.36 and RMSE = 2.14 for glycated albumin; r = 0.36 and RMSE = 2.22 for fructosamine). Associations of glycated albumin and fructosamine with HbA1c were relatively similar across CKD categories. CONCLUSIONS: In older adults with severe or very severe CKD, HbA1c, glycated albumin, and fructosamine were not highly correlated with fasting glucose. The results suggest there may be no particular advantage of glycated albumin or fructosamine over HbA1c for monitoring glycemic control in CKD.
Authors: Christopher J Hill; Alexander P Maxwell; Christopher R Cardwell; Barry I Freedman; Marcello Tonelli; Masanori Emoto; Masaaki Inaba; Yasuaki Hayashino; Shunichi Fukuhara; Tomonari Okada; Christiane Drechsler; Christoph Wanner; Anna Casula; Amanda I Adler; Claudia Lamina; Florian Kronenberg; Elani Streja; Kamyar Kalantar-Zadeh; Damian G Fogarty Journal: Am J Kidney Dis Date: 2013-08-16 Impact factor: 8.860
Authors: Lesley A Inker; Christopher H Schmid; Hocine Tighiouart; John H Eckfeldt; Harold I Feldman; Tom Greene; John W Kusek; Jane Manzi; Frederick Van Lente; Yaping Lucy Zhang; Josef Coresh; Andrew S Levey Journal: N Engl J Med Date: 2012-07-05 Impact factor: 91.245
Authors: Juan Jesús Carrero; Peter Stenvinkel; Lilian Cuppari; T Alp Ikizler; Kamyar Kalantar-Zadeh; George Kaysen; William E Mitch; S Russ Price; Christoph Wanner; Angela Y M Wang; Pieter ter Wee; Harold A Franch Journal: J Ren Nutr Date: 2013-03 Impact factor: 3.655
Authors: Christina M Parrinello; Pamela L Lutsey; David Couper; John H Eckfeldt; Michael W Steffes; Josef Coresh; Elizabeth Selvin Journal: Clin Chem Date: 2015-10-26 Impact factor: 8.327
Authors: James Ling; Jack K C Chung Ng; Eric S H Lau; Ronald C W Ma; Alice P S Kong; Andrea O Y Luk; Jeffrey S S Kwok; Cheuk-Chun Szeto; Juliana C N Chan; Elaine Chow Journal: Kidney Int Rep Date: 2022-04-06
Authors: Leila R Zelnick; Zona O Batacchi; Iram Ahmad; Ashveena Dighe; Randie R Little; Dace L Trence; Irl B Hirsch; Ian H de Boer Journal: Diabetes Care Date: 2020-08-11 Impact factor: 19.112
Authors: Michael Bergman; Muhammad Abdul-Ghani; Ralph A DeFronzo; Melania Manco; Giorgio Sesti; Teresa Vanessa Fiorentino; Antonio Ceriello; Mary Rhee; Lawrence S Phillips; Stephanie Chung; Celeste Cravalho; Ram Jagannathan; Louis Monnier; Claude Colette; David Owens; Cristina Bianchi; Stefano Del Prato; Mariana P Monteiro; João Sérgio Neves; Jose Luiz Medina; Maria Paula Macedo; Rogério Tavares Ribeiro; João Filipe Raposo; Brenda Dorcely; Nouran Ibrahim; Martin Buysschaert Journal: Diabetes Res Clin Pract Date: 2020-06-01 Impact factor: 5.602